MMI
About
About MMI
Symani uses two robotic arms carrying NanoWrist instruments with seven degrees of freedom at the tip. A surgeon operates the system from a seated console, and motion scaling converts larger hand movements into movements between seven and 20 times smaller at the instrument.
The platform filters tremor while preserving direct surgeon control during suturing, vessel connection and delicate tissue handling. It works with standard surgical microscopes and has been used in more than 1,000 clinical procedures across lymphatic, reconstructive and other microsurgical applications.
Articles
Products
- Symani Surgical System
Symani
Operations
Operating milestones
- Operating milestone
2026-10-08 - MMI disclosed 3,500 complex microsurgical procedures performed worldwide using Symani by October 8, 2026. - Worldwide Symani microsurgery
Source
Deployments
- Operating use
2026-10-08 - MMI reported approximately 50 Symani Surgical Systems installed worldwide as of its October 8 financing announcement. - Symani systems worldwide
Source
Funding
- 2026-10-08 - Series D - $125M - MMI raises $125 million Series D for Symani commercial expansion
BioStar Capital led the financing, with new investors S3 Ventures and Angelini Ventures joining an undisclosed strategic corporate investor and existing backers. - source: globenewswire.com
- 2026-09-16 - Strategic co-investment - $19.6M - MMI receives €17M EIB–Angelini Ventures co-investment
Medical Microinstruments received a new €17M co-investment from the European Investment Bank and Angelini Ventures to support its microsurgery robotics business. - source: angeliniventures.com
- 2024-02-21 - Series C - $110M - MMI completes Series C financing led by Fidelity
MMI completed Series C financing led by Fidelity Management & Research Company to expand Symani commercialization and clinical evidence. - source: mmimicro.com
- 2022-07-20 - Series B - $75M - MMI completes Series B financing for Symani commercialization
MMI completed Series B financing led by Deerfield Management to expand Symani commercialization and clinical development. - source: mmimicro.com
Investors
- BioStar Capital - Lead - VC - 3 funding events - repeat backer - first seen 2022-07-20 - latest 2026-10-08
- Andera Partners - Participant - VC - 2 funding events - repeat backer - first seen 2022-07-20 - latest 2024-02-21
- Angelini Ventures - Participant - VC - 2 funding events - repeat backer - first seen 2026-09-16 - latest 2026-10-08
- Deerfield Management - Lead - Angel / Individual - 2 funding events - repeat backer - first seen 2022-07-20 - latest 2024-02-21
- European Investment Bank - Participant - Government / Public - 2 funding events - repeat backer - first seen 2026-09-16 - latest 2026-10-08
- Fountain Healthcare Partners - Participant - VC - 2 funding events - repeat backer - first seen 2022-07-20 - latest 2024-02-21
- Panakès Partners - Participant - VC - 2 funding events - repeat backer - first seen 2022-07-20 - latest 2024-02-21
- RA Capital Management - Participant - VC - 2 funding events - repeat backer - first seen 2022-07-20 - latest 2024-02-21
- Sambatech - Participant - Unknown - 2 funding events - repeat backer - first seen 2022-07-20 - latest 2024-02-21
- Fidelity Management & Research Company - Lead - Unknown - 1 funding event - first seen 2024-02-21
- S3 Ventures - Participant - VC - 1 funding event - first seen 2026-10-08
- Wellington Partners - Participant - VC - 1 funding event - first seen 2024-02-21
Timeline
Events
- 2026-10-08 - Funding - MMI raises $125 million Series D for Symani commercial expansion
Approximately 50 Symani systems are installed, with 3,500 complex microsurgical procedures performed worldwide. Proceeds support expansion in the United States and other markets, clinical evidence including REMIND, and energy-instrument and digital-surgery development.
Source - 2026-09-16 - Funding - MMI receives €17M EIB–Angelini Ventures co-investment
The financing is the third completed investment under the investors’ €150M European life-sciences programme. MMI manufactures the Symani system in Pisa for microsurgery and super-microsurgery. EIB and Angelini Ventures each committed €75M to the six-year co-investment programme, which targets 7–10 European companies.
Source - 2026-07-30 - Regulatory - MMI receives FDA approval to expand REMIND microsurgery study
The supplement followed FDA review of 30-day safety data from the first patient cohort. REMIND evaluates Symani-enabled microsurgical techniques intended to re-establish deep-cervical lymphatic drainage in patients with Alzheimer's disease and confirmed lymphatic abnormalities. The study remains an early-feasibility investigation; Symani is not FDA-cleared for lymphatic reconstruction for brain disease.
Source - 2024-02-21 - Funding - MMI completes Series C financing led by Fidelity
All existing investors participated in the financing. The capital was allocated to high-growth-market commercialization, indication-expansion studies, advanced technology and global operations. The round extended the company’s funding base for microsurgery product and market expansion.
Source - 2022-07-20 - Funding - MMI completes Series B financing for Symani commercialization
RA Capital Management and BioStar Capital joined the round alongside Andera Partners, Fountain Healthcare Partners, Panakès Partners and Sambatech. The financing supported European commercialization, U.S. and Asia-Pacific market plans, and clinical research. MMI retained its Pisa Center of Excellence for research, manufacturing and other operations after redomiciling to the United States.
Source